81025-83-4

Basic information

• Product Name: (R)-(+)-3-METHYLSUCCINIC ACID 1-MONOMETHYL ESTER
• Synonyms: METHYL-(R)-3-CARBOXYBUTANOATE;4-METHYL HYDROGEN (R)-(+)-2-METHYLSUCCINATE;1-MONOMETHYL (R)-(+)-3-METHYLSUCCINATE;(R)-(+)-3-CARBOXYBUTYRIC ACID METHYL ESTER;(R)-(+)-3-METHYLSUCCINIC ACID 1-MONOMETHYL ESTER;(R)-(+)-2-METHYLSUCCINIC ACID 4-METHYL ESTER;(R)-2-METHYLSUCCINIC ACID 4-METHYL ESTER;(2R)-2-Methylsuccinic acid 4-methyl ester
• CAS NO: 81025-83-4
• Molecular Formula: C₆H₁₀O₄
• Molecular Weight: 146.14
• Product Categories: Carboxylic Acids (Chiral);Chiral Building Blocks;Synthetic Organic Chemistry;Chiral Building Blocks;Esters;Organic Building Blocks
• Mol File: 81025-83-4.mol
• Article Data: 34

Chemical Properties

• Boiling Point: 241-242 °C760 mm Hg(lit.)
• Flash Point: 101 °F
• Appearance: /
• Density: 1.150 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.00758mmHg at 25°C
• Refractive Index: n20/D 1.4320(lit.)
• Storage Temp.: Refrigerator
• CAS DataBase Reference: (R)-(+)-3-METHYLSUCCINIC ACID 1-MONOMETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(+)-3-METHYLSUCCINIC ACID 1-MONOMETHYL ESTER(81025-83-4)
• EPA Substance Registry System: (R)-(+)-3-METHYLSUCCINIC ACID 1-MONOMETHYL ESTER(81025-83-4)

Safety Data

• Hazard Codes: Xi
• Statements: 10-36/37/38
• Safety Statements: 26-36
• RIDADR: UN 3272 3/PG 3
• WGK Germany: 3
• Hazardous Substances Data: 81025-83-4(Hazardous Substances Data)

Usage

Uses

(R)-(+)-2-Methylsuccinic Acid 4-Methyl Ester is used in the preparation of triazole-containing macrocycles.

InChI:InChI=1/C6H10O4/c1-4(6(8)9)3-5(7)10-2/h4H,3H2,1-2H3,(H,8,9)/t4-/m1/s1

Upstream product

• 67-56-1 methanol 
• 4100-80-5 2-methylsuccinic anhydride 
• 97-65-4 2-methylenesuccinic acid 
• 623-43-8 crotonic acid methyl ester 
• 617-54-9 citraconic acid dimethyl ester 
• 498-23-7 citraconic acid 
• 22644-27-5 (R)-methylsuccinic acid dimethyl ester 
• 3641-51-8 2-(R)-methylsuccinic acid 
• 498-21-5 2-methylbutanedioic acid 
• 7338-27-4 4-methoxy-2-methylene-4-oxobutanoic acid 
• 21307-96-0 methyl 2-methylsuccinate 
• 143225-23-4 2(R)-Methyl-4-Benzyl Succinate 

Downstream Products

• 154634-38-5 (R,R)-2,3-dimethyl-succinic acid monomethyl ester 
• 1384132-79-9 (R)-(5-bromo-3-methylpent-1-ynyl)benzene 
• 1174194-07-0 (R)-3-methyl-5-phenylpent-4-yn-1-ol 
• 1351949-97-7 C₃₂H₄₄N₆O₆ 
• 1351949-91-1 C₂₂H₃₁N₅O₄ 
• 1351949-75-1 C₂₉H₃₇N₃O₅ 
• 1351949-59-1 C₁₉H₂₄N₂O₃ 
• 1351948-95-2 C₃₂H₄₂N₆O₆ 
• 1351948-90-7 C₂₂H₂₉N₅O₄ 
• 1351949-30-8 C₃₂H₄₂N₆O₆ 

Relevant articles and documents

Application of Transition-Metal Catalysis, Biocatalysis, and Flow Chemistry as State-of-the-Art Technologies in the Synthesis of LCZ696

LCZ696 is a novel treatment for patients suffering from heart failure that combines the two active pharmaceutical ingredients sacubitril and valsartan in a single chemical compound. While valsartan is an established drug substance, a new manufacturing process suitable for large-scale commercial production had to be developed for sacubitril. The use of chemocatalysis, biocatalysis, and flow chemistry as state-of-the-art technologies allowed to efficiently build up the structure of sacubitril and achieve the defined performance targets.

CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES

The present invention relates to Compounds of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R1, R2, R3, R4, Q and V are as defined herein. The present invention also relates to pharmaceutical compositions comprising a Compound of Formula (I) or Formula (II) and to their use in therapy.

Spirobenzylamine-Phosphine, Preparation Method Therefor And Use Thereof

The present invention relates to a spirobenzylamine-phosphine, preparation method therefor and use thereof. The compound has a structure represented by formula (I), wherein n=0 to 3; R1, R2, R3, R4, R5, R6, R7, R8 and R9 having a value as defined in claim 1. Starting from the substituted 7-trifluoromesyloxy-7′-diarylphosphino-1,1′-spiro-dihydroindene, the compound is synthesized in a two-step or three-step reactions. The new spirobenzylamine-phosphine is complexed with an iridium precursor and is subjected to ion exchange, to give an Iridium/spirobenzylamine-phosphine complex comprising various anions. The spiro benzyl amine-phosphine/Iridium complex according to the present invention may be used for catalyzing asymmetry hydrogenation of a variety of alpha-substituted acrylic acids, has high activity and enantio-selectivity, and has a good prospect of industrialization.